Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00006104 · ClinicalTrials.gov registry record · Phase 2

Trastuzumab Plus Docetaxel in Treating Women With Recurrent or Metastatic Breast Cancer

A Phase 2 study of Breast Cancer, sponsored by Vanderbilt-Ingram Cancer Center.

Completed
Registry status
Phase 2
Development phase
46
Enrollment target
15
Study locations

NCT00006104 is a Phase 2 study of Breast Cancer that has completed, run by Vanderbilt-Ingram Cancer Center. The registered enrollment target is 46 participants, below the 2,803-participant average among 1,224 other Breast Cancer trials with a reported enrollment target (98% lower). The trial reports 15 study locations across 5 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00006104, a Phase 2 study of Breast Cancer, has completed, sponsored by Vanderbilt-Ingram Cancer Center.

COMPLETED
Registry status
Phase 2
Development phase
46 participants
Enrollment target
15
Study locations

Study Summary

RATIONALE: Monoclonal antibodies such as trastuzumab can locate tumor cells and either kill them or deliver tumor-killing substances to them without harming normal cells. Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining chemotherapy with monoclonal antibody therapy may kill more tumor cells. PURPOSE: Phase II trial to study the effectiveness of trastuzumab plus docetaxel in treating women who have recurrent or metastatic breast cancer.

Conditions Studied

Breast Cancer

Interventions

  • DRUG docetaxel
  • BIOLOGICAL trastuzumab

Study Locations (15)

Tennessee

  • Erlanger Health Systems - Chattanooga
  • Memorial Health Care System - Chattanooga
  • Williamson Medical Center - Franklin
  • Jackson-Madison County Hospital - Jackson
  • Methodist/Thompson Oncology Research - Knoxville
  • Tennessee Cancer Specialists - Knoxville
  • Boston Baskin Cancer Group - Memphis
  • St. Thomas Health Services - Nashville
  • Vanderbilt-Ingram Cancer Center - Nashville
  • Methodist Medical Center of Oak Ridge - Oak Ridge

Illinois

  • Robert H. Lurie Comprehensive Cancer Center, Northwestern University - Chicago
  • Evanston Hospital - Evanston

Alabama

  • Providence Hospital - Mobile

Kentucky

  • Owensboro Medical Health System - Owensboro

Pennsylvania

  • Fox Chase Cancer Center - Philadelphia

Trial Details

FieldValue
Enrollment Target 46 participants
Start Date 1998-09
Est. Completion 2003-07
Phase Phase 2

Sponsor

Vanderbilt-Ingram Cancer Center

189 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT00006104

The ClinicalTrials.gov registry entry for NCT00006104 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 46 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 2,803-participant average among 1,224 other Breast Cancer trials with a reported enrollment target (98% lower). The listed sponsor is Vanderbilt-Ingram Cancer Center, which has 189 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Breast Cancer appearing as the primary indexed condition, and to 2 interventions - of which docetaxel is the first listed.

NCT00006104 reports 15 study locations spanning 5 distinct geographic areas - top geographies include Tennessee, Illinois, Alabama.

Frequently Asked Questions

What is clinical trial NCT00006104 about?

NCT00006104 is a clinical study titled "Trastuzumab Plus Docetaxel in Treating Women With Recurrent or Metastatic Breast Cancer". RATIONALE: Monoclonal antibodies such as trastuzumab can locate tumor cells and either kill them or deliver tumor-killing substances to them without harming normal cells. Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining chemothera...

What is the current status of trial NCT00006104?

This trial is currently completed. It is a Phase 2 study. The enrollment target is 46 participants. The study started on 1998-09. Estimated completion is 2003-07.

What conditions does trial NCT00006104 study?

This clinical trial studies the following conditions: Breast Cancer.

What interventions are being tested in trial NCT00006104?

The interventions under investigation include: docetaxel (DRUG), trastuzumab (BIOLOGICAL).

Who is sponsoring clinical trial NCT00006104?

This trial is sponsored by Vanderbilt-Ingram Cancer Center, which has 189 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00006104 being conducted?

This trial has 15 study locations across Alabama, Illinois, Kentucky, Pennsylvania, Tennessee. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Breast Cancer

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Breast Cancer

All registered trials for this condition

Alabama

All trials with a study site in Alabama

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.